Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Dr. Phillip Frost is a Genius .Follow what the smart people are doing

|Includes: OPKO Health, Inc. (OPK)

There are many strategies to investing. The market looks forward for innovation, growth and Sales. I also like to follow top CEO's in the business community. We all know Steve Jobs, John Chambers and Warren Buffet. A hidden star is Dr Phillip Frost. 

Dr. Frost became the CEO and Chairman of OPKO Health, Inc. upon the consummation of the merger of Acuity Pharmaceuticals Inc., Froptix Corporation and exegenics, Inc. on March 27, 2007 . Dr. Frost was named the Chairman of the Board of Teva Pharmaceutical Industries, (NASDAQ:TEVA) in March 2010 and had previously been Vice Chairman since January 2006 when Teva acquired IVAX Corporation.

OPKO Health, Inc., a specialty healthcare company, engages in the discovery, development, and commercialization of pharmaceutical products, medical devices, vaccines, diagnostic technologies, and imaging systems for treatment and management of ophthalmic diseases. Its product candidates include Rolapitant, which is in Phase III clinical trial to treat emesis; Bevasiranib that is in Phase III clinical trials for the treatment of wet age-related macular degeneration (Wet AMD); Doxovir, which is in Phase II clinical trials for viral conjunctivitis; SCH 900978 that is in Phase II clinical trials for emesis; and ACU-HHY-011 to treat wet AMD. The company’s products under pre-clinical stage of development comprise Alzheimer’s test for Alzheimer’s diagnostic; flu vaccine for the treatment of pan-influenza; and OPK-HVB-004 and OPK-HVB-010 to treat wet AMD/diabetic retinopathy/diabetic macular edema. It also offers ophthalmic diagnostic systems and instrumentation products, including spectral OCT SLO combination imaging system and ultrasound products; and develops Aquashunt, a shunt used in the treatment of refractory open angle glaucoma. The company sells ophthalmic instruments, imaging products, and other medical devices to various eye care practitioners, including retinal and glaucoma specialists, ophthalmologists, optometrists, retail optometry chain outlets, teaching institutions, and military hospitals. It has strategic license agreements with the University of Texas, Southwestern Medical Center, Academia Sinica, the University of Pennsylvania, the University of Florida Research Foundation, and Redox Pharmaceuticals. The company was founded in 2006 and is headquartered in Miami, Florida.

My strategy is simple. With the new position as Chairman of the Board of Teva for Dr Frost and a deep understanding of the pipeline of Opko, look for Teva to play a bigger role in Opko's future

Opko stock trades at $2.35..The 50 day moving average is $2.05 and the 200 day moving average is $1.98..QYQ growth of 300 % and a cash balance of 42 Million.

This is a Buy and Hold

Disclosure: long OPK

Disclosure: Long OPKO

Disclosure: long OPK